Executive Summary: The Section 232 "TrumpRx" CrisisOn April 2, 2026, a sweeping Proclamation adjusted the import landscape for pharmaceutical ingredients under Section 232 of the Trade Expansion Act. The mandate is clear: imports of patented pharmaceutical products and their associated ingredients n
Executive Summary: The New "Green" Barrier in B2B SourcingIn the global pharmaceutical landscape of 2026, the "lowest price" is no longer the final price. The implementation of the Carbon Border Adjustment Mechanism (CBAM) has introduced a carbon-based tariff on goods imported into the EU, with simi
Executive Summary: The Procurement Crisis of 2026As we navigate the second quarter of 2026, the global pharmaceutical intermediate market has entered a phase of "Mirage Stability." While demand for certain bulk commodities appears to be stabilizing, the specialty segment—specifically for Cyclopentan